109 related articles for article (PubMed ID: 10974724)
1. Eligibility audits for the randomized neuropathic bone pain trial (TROG 96.05).
Roos DE; Davis SR; O'Brien PC; Hoskin PJ; Spry NA; Burmeister BH; Turner SL; Bernshaw DM
Australas Radiol; 2000 Aug; 44(3):303-7. PubMed ID: 10974724
[TBL] [Abstract][Full Text] [Related]
2. Quality assurance experience with the randomized neuropathic bone pain trial (Trans-Tasman Radiation Oncology Group, 96.05).
Roos DE; Davis SR; Turner SL; O'Brien PC; Spry NA; Burmeister BH; Hoskin PJ; Ball DL
Radiother Oncol; 2003 May; 67(2):207-12. PubMed ID: 12812852
[TBL] [Abstract][Full Text] [Related]
3. A role for radiotherapy in neuropathic bone pain: preliminary response rates from a prospective trial (Trans-tasman radiation oncology group, TROG 96.05).
Roos DE; O'Brien PC; Smith JG; Spry NA; Hoskin PJ; Burmeister BH; Turner SL; Bernshaw DM
Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):975-81. PubMed ID: 10705020
[TBL] [Abstract][Full Text] [Related]
4. Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05).
Roos DE; Turner SL; O'Brien PC; Smith JG; Spry NA; Burmeister BH; Hoskin PJ; Ball DL;
Radiother Oncol; 2005 Apr; 75(1):54-63. PubMed ID: 15878101
[TBL] [Abstract][Full Text] [Related]
5. Costing the components of pain management: analysis of Trans-Tasman Radiation Oncology Group trial (TROG 96.05): one versus five fractions for neuropathic bone pain.
Pollicino CA; Turner SL; Roos DE; O'Brien PC
Radiother Oncol; 2005 Sep; 76(3):264-9. PubMed ID: 16153729
[TBL] [Abstract][Full Text] [Related]
6. A quality assurance audit: phase III trial of maximal androgen deprivation in prostate cancer (TROG 96.01).
Steigler A; Mameghan H; Lamb D; Joseph D; Matthews J; Franklin I; Turner S; Spry N; Poulsen M; North J; Kovacev O; Denham J
Australas Radiol; 2000 Feb; 44(1):65-71. PubMed ID: 10761262
[TBL] [Abstract][Full Text] [Related]
7. Quality assurance audit: a prospective non-randomised trial of chemotherapy and radiotherapy for osteolymphoma (TROG 99.04/ALLG LY02).
Christie D; Le T; Watling K; Cornes D; O'Brien P; Hitchins R
J Med Imaging Radiat Oncol; 2009 Apr; 53(2):203-6. PubMed ID: 19527368
[TBL] [Abstract][Full Text] [Related]
8. Radiotherapy for neuropathic pain due to bone metastases.
Roos DE
Ann Palliat Med; 2015 Oct; 4(4):220-4. PubMed ID: 26541402
[TBL] [Abstract][Full Text] [Related]
9. Prospective randomised multicenter trial on single fraction radiotherapy (8 Gy x 1) versus multiple fractions (3 Gy x 10) in the treatment of painful bone metastases.
Kaasa S; Brenne E; Lund JA; Fayers P; Falkmer U; Holmberg M; Lagerlund M; Bruland O
Radiother Oncol; 2006 Jun; 79(3):278-84. PubMed ID: 16793154
[TBL] [Abstract][Full Text] [Related]
10. Quality assurance audit in an Australasian phase III trial of accelerated radiotherapy for head and neck cancer (TROG 91.01). Trans-Tasman Radiation Oncology Group.
Hamilton C; Poulsen M; Walker Q; Krawitz H; Hindley A; Spry N; Peters L; Lamb D; Denham J; Steigler A
Australas Radiol; 1999 May; 43(2):227-32. PubMed ID: 10901907
[TBL] [Abstract][Full Text] [Related]
11. Implementing the UK Medical Research Council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer.
Sydes MR; Stephens RJ; Moore AR; Aird EG; Bidmead AM; Fallowfield LJ; Graham J; Griffiths S; Mayles WP; McGuire A; Stanley S; Warrington AP; Dearnaley DP;
Radiother Oncol; 2004 Aug; 72(2):199-211. PubMed ID: 15297138
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases.
Wu JS; Wong R; Johnston M; Bezjak A; Whelan T;
Int J Radiat Oncol Biol Phys; 2003 Mar; 55(3):594-605. PubMed ID: 12573746
[TBL] [Abstract][Full Text] [Related]
13. Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial.
Chow E; van der Linden YM; Roos D; Hartsell WF; Hoskin P; Wu JS; Brundage MD; Nabid A; Tissing-Tan CJ; Oei B; Babington S; Demas WF; Wilson CF; Meyer RM; Chen BE; Wong RK
Lancet Oncol; 2014 Feb; 15(2):164-71. PubMed ID: 24369114
[TBL] [Abstract][Full Text] [Related]
14. Do screening trial recruitment logs accurately reflect the eligibility criteria of a given clinical trial? Early lessons from the RAVES 0803 trial.
Sundaresan P; Turner S; Kneebone A; Pearse M; Fraser-Browne C; Woo HH
Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):348-52. PubMed ID: 24685345
[TBL] [Abstract][Full Text] [Related]
15. Accrual to Trans-Tasman Radiation Oncology Group-sponsored trials 2010-2012.
Christie DR
J Med Imaging Radiat Oncol; 2013 Aug; 57(4):499-502. PubMed ID: 23870351
[TBL] [Abstract][Full Text] [Related]
16. Quality assurance in the EORTC phase III randomised 'boost vs. no boost' trial for breast conserving therapy: comparison of the results of two individual case reviews performed early and late during the accrual period.
Poortmans PM; Ataman F; Davis JB; Bartelink H; Horiot JC; Pierart M; Collette L; Van Tienhoven G
Radiother Oncol; 2005 Sep; 76(3):278-84. PubMed ID: 15919127
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases.
Hartsell WF; Scott CB; Bruner DW; Scarantino CW; Ivker RA; Roach M; Suh JH; Demas WF; Movsas B; Petersen IA; Konski AA; Cleeland CS; Janjan NA; DeSilvio M
J Natl Cancer Inst; 2005 Jun; 97(11):798-804. PubMed ID: 15928300
[TBL] [Abstract][Full Text] [Related]
18. Continuing reluctance to use single fractions of radiotherapy for metastatic bone pain: an Australian and New Zealand practice survey and literature review.
Roos DE
Radiother Oncol; 2000 Sep; 56(3):315-22. PubMed ID: 10974380
[TBL] [Abstract][Full Text] [Related]
19. Optimizing Radiation Therapy Quality Assurance in Clinical Trials: A TROG 08.03 RAVES Substudy.
Trada Y; Kneebone A; Paneghel A; Pearse M; Sidhom M; Tang C; Wiltshire K; Haworth A; Fraser-Browne C; Martin J
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1045-51. PubMed ID: 26475066
[TBL] [Abstract][Full Text] [Related]
20. 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient follow-up. Bone Pain Trial Working Party.
Radiother Oncol; 1999 Aug; 52(2):111-21. PubMed ID: 10577696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
